Annual Benefit Report

Overview

The report describes the company’s 2019 progress toward regulatory approval and commercialization of the iLet Bionic Pancreas System, including FDA authorization for home-use clinical testing of its Gen 3 bihormonal configuration. It also reports $63 million in additional institutional investment, completing a Series B/B-2 raise totaling slightly more than $126 million. The report further documents Beta Bionics’ certified B Corporation status and its 2019 assessment cycle for recertification in 2020.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2019
Period: Ends 31 December 2019
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Standards

Other

Materiality

Assessment
Basis

Assurance

Standard
Scope
Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services